News | Radiation Therapy | April 26, 2019

2018 ASTRO survey shows practicing radiation oncologists believe prior authorization adds to patient, physician stress

Radiation Oncologists Say Prior Authorization Delays Patient Access to Cancer Treatments

April 26, 2019 — Restrictive prior authorization practices cause unnecessary delays and interference in care decisions for cancer patients, according to a new survey of nearly 700 radiation oncologists — released by the American Society for Radiation Oncology (ASTRO).

Nearly all radiation oncologists (93 percent) said that their patients are delayed from life-saving treatments, and a third (31 percent) said the average delay lasts longer than five days – a full week of standard radiation treatments. These delays cause added stress and anxiety to patients already concerned about their health. They are cause for alarm given research linking each week of delay in starting cancer therapy with a 1.2 percent to 3.2 percent increased risk of death.

In addition to prevalent treatment delays, the ASTRO physician survey illuminates other ways prior authorization negatively impacts patient outcomes and takes physicians away from caring for their patients:

Added Patient Stress

  • More than 7 in 10 radiation oncologists (73 percent) said their patients regularly express concern to them about the delay caused by prior authorization;

  • More than 3 in 10 radiation oncologists (32 percent) have been forced to use a different therapy for a substantial number of their patients (>10 percent) due to prior authorizations delays.

Unnecessary Delay Tactics

  • Nearly two-thirds of radiation oncologists (62 percent) said most denials they receive from prior authorization review are overturned on appeal;

  • Radiation oncology benefit management companies (ROBMs) required 85 percent of radiation oncologists to generate multiple treatment plans, which require physicians and medical physicists to spend several hours developing alternatives to their recommended course of treatment;

  • More than 4 in 10 respondents (44 percent) said their peer reviews typically are not conducted by a licensed radiation oncologist.

Wasting Physician Time

  • Nearly one in five radiation oncologists (17 percent) said they lose more than 10 percent of time that they could be caring for their patients focused instead on dealing with prior authorization issues. An additional 39 percent spend 5-10 percent of their average workday on prior authorization;

  • More than 4 in 10 radiation oncologists (44 percent) needed prior authorization for at least half of their treatment recommendations. An additional third (37 percent) needed it for at least a quarter of their cases;

  • Many radiation oncologists (63 percent) had to hire additional staff in the last year to manage the prior authorization process.

Disproportionate Impact on Patients at Community-Based Clinics

  • Patients treated at community-based, private practices experience longer delays than those seen at academic centers. For example, average treatment delays lasting longer than a week were reported by 34 percent of private practitioners vs. 28 percent of academic physicians (p=0.005);

  • Radiation oncologists in private practice are almost twice as likely to spend more than 10 percent of their day focused on prior authorization, compared to physicians at academic centers (23 percent vs. 13 percent, p=0.003)

“This survey makes clear that restrictive prior authorization practices can cause unnecessary, stressful and potentially life-threatening delays for cancer patients,” said Paul Harari, M.D., FASTRO, chair of the ASTRO board of directors and professor and chairman of human oncology at the University of Wisconsin-Madison. "While the system may have been designed as a path to streamline and strengthen healthcare, it is in fact frequently harmful to patients receiving radiation therapy. In its current form, prior authorization causes immense anxiety and wastes precious time for cancer patients.”

“Radiation oncology and cancer patients have been particularly hard hit by prior authorization’s unnecessary burden and interference in care decisions,” said Vivek Kavadi, M.D., vice chair of ASTRO’s Payer Relations Subcommittee and a radiation oncologist at Texas Oncology. “Radiation oncologists increasingly are restricted from exercising our clinical judgment in what is in the best interest of the patient, yet we are held accountable for the outcomes of treatments where decisions have been taken out of our hands.”

In the 2018 annual ASTRO member survey, radiation oncologists named prior authorization as the greatest challenge facing the field. The burden was especially prominent among private practitioners in community-based settings, where the majority of cancer patients receive care.

An online survey was sent by email to all 3,882 U.S.-based, practicing radiation oncologists in ASTRO’s member database, and 620 physicians completed the survey online. Invitations were sent in December 2018, with one email reminder in January 2019, and the survey closed in February 2019. ASTRO staff also administered paper surveys at the ASTRO Annual Meeting in October 2018 and collected 53 responses. Findings reflect the combined total of 673 radiation oncologist responses.

The findings from ASTRO’s new physician survey align with recent reports from the American Medical Association (AMA), American Cancer Society Cancer Action Network (ACS CAN) and others, demonstrating the pervasiveness of prior authorization obstacles throughout the American healthcare system.

ASTRO recently signed onto a letter with the AMA and other medical societies calling for the Centers for Medicare and Medicaid Services (CMS) to require Medicare Advantage plans to align their prior authorization requirements with a Consensus Statement on Improving the Prior Authorization Process authored jointly by leading provider and payer organizations.

Read the executive summary of the ASTRO survey

For more information: www.astro.org


Related Content

News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Lung Imaging

April 17, 2024 — A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients ...

Time April 17, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Therapy

April 12, 2024 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery, and ...

Time April 12, 2024
arrow
News | Artificial Intelligence

April 9, 2024 —PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for ...

Time April 09, 2024
arrow
News | Artificial Intelligence

April 8, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...

Time April 08, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a snapshot of the Top 10 most-read content from ITN's viewers during the month of March: 1. Philips Teams with ...

Time April 04, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
Subscribe Now